Can a Chemical in Red Wine Help Prevent Cancer, Diabetes and Heart Disease? Studies Revealed at University of Leicester
Published: Oct 10, 2012
It brings together researchers from all over the world to share, discuss and summarize the last two years of scientific work in the area of resveratrol – a compound found in grapes and red wine.
The red wine miracle compound, resveratrol, is keeping both scientists and the health industry very busy. Since 2010, a number of clinical trials have shown potential disease prevention effects for resveratrol in humans. Evidence from more than ten of these recent clinical trials will be presented and discussed at Resveratrol 2012, the 2nd International Scientific Conference on Resveratrol and Health, at Leicester University, 5-7 December, 2012.
Even though resveratrol is a comparatively simple compound found in wine, grapes, peanuts and berries, it has complex and beneficial effects on the human body. Recommendations from the first international conference on resveratrol held in Denmark, Resveratrol2010, were that the benefits seen in animal models had to be proven in humans. At that time there was not yet a scientific basis to say that resveratrol has a disease preventative or therapeutic effect in humans, nor that resveratrol could extend human life. The scientific working group from Resveratrol2010 recognized the strong preventive effects of resveratrol as observed in experimental animals in four areas: Cancer in the colon and skin, Coronary-hearth disease, Diabetes, and Neuro-protection. The big issue in 2010 was that no human trials on resveratrol were available.
Therefore, the scientific working group from Resveratrol2010 recommended initiating human clinical trials to test the preventive effect of resveratrol. A number of clinical trials have now been established since September 2010. While these trials involve only small numbers of participants receiving short-term access to resveratrol, the most crucial findings are that these first clinical trials support the preventive effects already established in experimental animals.
Now, two years later, the 2nd International Scientific Conference on Resveratrol and Health, Resveratrol2012, will take place in Leicester, UK, in December 2012. Here, data from more than ten of these clinical trials will be presented and discussed. These new clinical trials will be invaluable for the formulation of the next set of recommendations for resveratrol.
The chair of the Scientific Committee for Resveratrol2012, Associate Professor Ole Vang, Roskilde University, Denmark, recalls, “A few months before our conference in 2010, I suggested that a number of clinical trials on resveratrol would be presented at this first conference, but only a single human study concerning treatment with resveratrol for one month was included. I was little disappointed at that time. But over the last two years the clinical data has started to roll in”.
At Resveratrol2012, there will be more than 65 lectures, presentations and posters by different researchers from all over the world. The leading names in the area of resveratrol will be present to set the agenda for resveratrol market, R&D as well as innovation for the next coming years.
Resveratrol2012 will bring together researchers and experts from all over the world to share, discuss and summarize the last two years of scientific work in the area of resveratrol. Other than offering great opportunities for knowledge sharing and networking, the conference will produce a selection of reports with the latest update on global resveratrol research, as well as the next set of recommendations for the coming year's scientific research and the use of resveratrol.
For the program and other details please visit http://www.resveratrol2012.eu/
For more information:
Assoc. Prof. Ole Vang
+45 4674 2552